MedTrace Logo

Effectiveness of Premedication on the Success Rate of Inferior Alveolar Nerve Block

NCT05097768 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2022-02-14

No results posted yet for this study

Summary

Purpose: The aim of this prospective, double-blind, randomized controlled trial is to compare the effect of oral premedication of dexamethasone, ketorolac, meloxicam, ibuprofen or placebo on the success of inferior alveolar nerve blocks (IANB) of mandibular posterior teeth in patients experiencing symptomatic irreversible pulpitis. Methods: The trial will include five study groups, each consists of 50 patients who exhibits symptomatic irreversible pulpitis of a mandibular first or second molar. The patients will receive identically appearing capsules containing either dexamethasone 0.5 mg, ketorolac 10 mg, meloxicam 7.5 mg, ibuprofen 600 mg, or placebo by mouth 60 minutes before the administration of an IANB. Endodontic access will begin 15 minutes after completion of the IANB. The IANB success is defined as no or mild pain (Heft Parker visual analog scale recordings) on pulpal access or instrumentation.

Conditions

  • Symptomatic Irreversible Pulpitis

Interventions

DRUG

Dexamethasone 0.5mg

The patients will be randomly given the medication by mouth 60 min before administering IANB.

DRUG

Ketorolac 10 Mg Oral Tablet

The patients will be randomly given the medication by mouth 60 min before administering IANB.

DRUG

Meloxicam 7.5 mg

The patients will be randomly given the medication by mouth 60 min before administering IANB.

DRUG

Ibuprofen 600 mg

The patients will be randomly given the medication by mouth 60 min before administering IANB.

DRUG

Placebo

The patients will be randomly given the medication by mouth 60 min before administering IANB.

Sponsors & Collaborators

  • Alfarabi Colleges

    lead OTHER

Principal Investigators

  • Amr M Elnaghy, PhD · Vision Colleges

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-15
Primary Completion
2022-01-15
Completion
2022-01-27

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05097768 on ClinicalTrials.gov